Breast Imaging

What Is the Best Breast Cancer Screening for an Intermediate-Risk Transmasculine Patient?

·
What Is the Best Breast Cancer Screening for an Intermediate-Risk Transmasculine Patient?

A 32-year-old transmasculine patient presents for a primary care visit. He has a personal history of atypical ductal hyperplasia (ADH) diagnosed five years ago and underwent a reduction mammoplasty as part of his gender-affirming care. He has been on testosterone therapy for several years. You know his risk is elevated, and he is over 30, but he has not had a bilateral mastectomy. The clinical question is clear: what is the most appropriate imaging study for breast cancer screening in this specific intermediate-risk scenario? According to the American College of Radiology (ACR) Appropriateness Criteria, the answer is definitive. For this patient, Digital breast tomosynthesis screening is rated Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies to a specific patient population: transmasculine (female-to-male) individuals who are 30 years of age or older and have an intermediate lifetime risk of developing breast cancer. This risk level is defined by factors such as a personal history of lobular neoplasia (including lobular carcinoma in situ), atypical ductal hyperplasia (ADH), or a calculated lifetime risk between 15% and 20% based on risk models.

Crucially, this workflow is for patients who have residual breast tissue. This includes individuals who have had no chest surgery or those who have undergone a reduction mammoplasty, which reduces but does not eliminate breast parenchyma. The presence of this tissue is the basis for screening recommendations.

This article does not apply to several similar-looking scenarios:

  • Transmasculine patients with bilateral mastectomies (“top surgery”): These individuals have minimal residual breast tissue, and routine screening mammography is generally not performed. Their clinical pathway is distinct.
  • Transmasculine patients at average risk: For those without intermediate-risk factors, screening typically begins at age 40, aligning with guidelines for cisgender women.
  • Transfeminine (male-to-female) patients: Screening guidelines for this population are different, based primarily on age and duration of hormone therapy.

What Diagnoses Are You Working Up in This Scenario?

The primary goal of screening in this intermediate-risk patient is the early detection of breast cancer before it becomes clinically apparent. Because the patient has retained breast tissue, they remain at risk for the same types of breast malignancies as cisgender women, though the hormonal milieu is different.

Ductal Carcinoma in Situ (DCIS) and Invasive Ductal Carcinoma (IDC): These are the most common forms of breast cancer. The patient’s history of ADH significantly increases the risk for these malignancies. Screening aims to detect microcalcifications or small masses that could represent early-stage disease, when treatment is most effective.

Invasive Lobular Carcinoma (ILC): While less common than ductal cancers, ILC can be more challenging to detect on mammography. A personal history of lobular neoplasia is a specific risk factor. Digital breast tomosynthesis can improve the detection of the subtle architectural distortion often associated with ILC.

Benign Post-Surgical Changes vs. Malignancy: In a patient with a history of reduction mammoplasty, a key diagnostic challenge is differentiating benign post-operative changes from a new malignancy. Scar tissue, architectural distortion, and fat necrosis are expected findings but can sometimes mimic or obscure a cancerous lesion. Effective screening must be able to navigate this altered anatomy.

Why Is Digital Breast Tomosynthesis the Recommended Study for This Presentation?

For an intermediate-risk transmasculine patient with remaining breast tissue, the ACR designates Digital breast tomosynthesis (DBT) screening as Usually Appropriate. Standard 2D mammography screening also receives this rating, but DBT is often preferred due to its enhanced visualization capabilities, particularly in complex cases.

DBT, or 3D mammography, acquires images of the breast from multiple angles and reconstructs them into a series of thin slices. This “un-stacking” of tissue is highly effective at reducing the impact of overlapping breast parenchyma, which can hide cancers on a standard 2D mammogram. For a patient with surgically altered breasts from a reduction mammoplasty, where scar tissue can create architectural distortion, DBT’s ability to clarify these areas is a significant advantage. It helps distinguish true lesions from benign post-surgical changes, which can reduce the need for unnecessary callbacks and additional imaging.

Both DBT and standard mammography involve a low level of ionizing radiation (ACR relative radiation level ☢☢, corresponding to an effective dose of 0.1-1 mSv). The clinical benefit of early cancer detection in this intermediate-risk group far outweighs the minimal radiation risk.

Alternative imaging modalities are rated lower for this specific screening scenario:

  • Breast Ultrasound (US) and MRI breast without and with IV contrast are rated as May be appropriate. While both are valuable tools, they are not the primary screening modality here. Ultrasound is often used as a supplemental or diagnostic tool to evaluate a specific finding on mammography. Contrast-enhanced MRI is typically reserved for high-risk screening (lifetime risk >20%) due to its higher sensitivity but lower specificity, which can lead to more false positives and subsequent biopsies.
  • MRI breast without IV contrast is rated Usually not appropriate for screening, as it lacks the necessary diagnostic information to reliably detect suspicious enhancing lesions.

The goal is to leverage the most effective primary screening tool. For detailed technical considerations on performing this study, see our comprehensive guide to the Screening Mammography (with DBT) protocol.

What’s Next After Digital Breast Tomosynthesis? Downstream Workflow

The results of the DBT will be categorized using the Breast Imaging Reporting and Data System (BI-RADS) score, which dictates the next steps in the clinical workflow.

  • Negative or Benign Finding (BI-RADS 1 or 2): If the screening is negative or shows clearly benign findings (like stable post-surgical clips or benign calcifications), no further immediate action is needed. The patient should continue with annual screening mammography.
  • Incomplete Assessment (BI-RADS 0): This result means the radiologist needs more information to make a final assessment. This is common, especially on a first screening after surgery. The patient will be called back for additional imaging, which typically includes diagnostic mammographic views (e.g., spot compression, magnification) and/or a targeted breast ultrasound of the area in question.
  • Probably Benign Finding (BI-RADS 3): This indicates a finding that has a very high probability of being benign (<2% risk of malignancy). The standard recommendation is a short-interval follow-up, usually with a repeat mammogram or ultrasound in six months, to ensure stability.
  • Suspicious or Highly Suggestive of Malignancy (BI-RADS 4 or 5): These findings warrant a biopsy for definitive pathologic diagnosis. The patient should be referred promptly for a tissue sampling procedure, most commonly an ultrasound-guided or stereotactic (mammogram-guided) core needle biopsy.

This structured reporting and follow-up pathway ensures that any potential abnormalities are addressed systematically, balancing the need for early detection with the avoidance of unnecessary procedures.

Pitfalls to Avoid (and When to Get Help)

Several potential pitfalls can complicate care in this specific clinical scenario. Awareness can help ensure an accurate and timely diagnosis.

  • Misclassifying Patient Risk: Failing to recognize a personal history of ADH or LCIS as an intermediate-risk factor can lead to delayed screening initiation (e.g., waiting until age 40) or using an average-risk protocol.
  • Incomplete Clinical History: Not clearly communicating the patient’s history of reduction mammoplasty to the radiologist can hinder interpretation. The radiologist needs this context to correctly interpret expected findings like scar tissue and architectural distortion.
  • Conflating Screening with Diagnostic Workup: If the patient presents with a new palpable lump, pain, or nipple discharge, a screening mammogram is insufficient. This patient requires a diagnostic workup, which starts with diagnostic mammography and targeted ultrasound, regardless of their screening schedule.
  • Ignoring Gender Identity in Communication: Ensure all communication with the patient and the imaging center uses the patient’s correct name and pronouns. A negative or unwelcoming experience can be a significant barrier to continued engagement in necessary screening.

If a palpable lump is discovered on physical exam, escalate immediately to a diagnostic imaging pathway.

Related ACR Topics and Tools

Navigating imaging decisions requires access to reliable, evidence-based resources. For a broader overview of imaging recommendations across all transgender patient populations, see our parent guide. For other tools to assist in ordering and patient communication, explore the resources below.

Frequently Asked Questions

Does testosterone therapy eliminate the need for breast cancer screening in transmasculine patients?

No. While testosterone therapy reduces endogenous estrogen and can cause breast tissue to atrophy, it does not eliminate breast cancer risk, especially in individuals with residual breast parenchyma after no surgery or a reduction mammoplasty. The underlying risk from factors like a personal history of ADH or LCIS persists.

Why is screening initiated at age 30 in this intermediate-risk scenario, not 40?

The recommendation to begin screening at age 30 is based on the patient’s intermediate-risk status. Risk factors like a personal history of atypical ductal hyperplasia or lobular neoplasia increase the likelihood of developing breast cancer at an earlier age. This is consistent with guidelines for cisgender women with the same risk factors.

How does a prior reduction mammoplasty affect the mammogram?

A reduction mammoplasty alters the breast’s architecture. Radiologists will expect to see post-surgical scarring, skin thickening, and potential fat necrosis. These can sometimes mimic or obscure malignancies. This is a key reason why Digital Breast Tomosynthesis (DBT) is particularly valuable, as its 3D views help differentiate true lesions from benign post-operative changes.

If this patient had a lifetime risk of 25%, would the recommendation change?

Yes. A lifetime risk greater than 20% categorizes a patient as high-risk, not intermediate-risk. In that scenario, annual screening with contrast-enhanced breast MRI is often recommended in addition to annual mammography, as MRI has higher sensitivity for cancer detection in high-risk populations.

Is a chest wall physical exam still necessary for these patients?

Absolutely. A thorough clinical breast exam (or chest wall exam) remains a critical component of care. It can detect palpable abnormalities that may not be visible on imaging. Any new palpable finding should trigger a diagnostic imaging workup, not just a routine screening.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026